Additional file 2: Figure S1. of Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
- Julian Halcox (4115842)
- José Banegas (4115839)
- Carine Roy (84997)
- Jean Dallongeville (224373)
- Guy Backer (4115836)
- Eliseo Guallar (27363)
- Joep Perk (693176)
- David Hajage (340017)
- Karin Henriksson (4115833)
- Claudio Borghi (654027)
Publication date
June 2017
DOIAbstract
Proportion of non-statin-treated patients with markers of atherogenic dyslipidemia, according to T2DM status, CVD risk, and age: (a) according to SCORE-HDL categories; (b) according to ACC/AHA categories. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and <1.3 mmol/l in women. Abbreviations: ACC American College of Cardiology, AHA American Heart Association, CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, SCORE-HDL Systematic Coronary Risk Evaluation-high-density lipoprotein, T2DM type 2 diabetes mellitus, TG triglycerides (PDF 1099 kb
Add to ORKG